Fig. 3.

Factors associated with ≥ 5% BW loss in patients treated with SGLT2i. Multivariate analysis indicated that the use of diuretics, old age, a high-dose SGLT2i, use of empagliflozin in relative to dapagliflozin, higher estimated glomerular filtration rate, and higher BMI were independent factors associated with a BW loss of $\ge$ 5.0%, whereas use of insulin or metformin was independently associated with a lower risk of BW loss of $\ge$ 5.0% following SGLT2i initiation. ALT: aminotransferases; BMI: body mass index; BW: body weight; eGFR: estimated glomerular filtration rate; HbA1c: hemoglobin A1c; MRA: mineralocorticoid receptor antagonist; SGLT2i: sodium–glucose cotransporter 2 inhibitors; TZD: thiazolidinedione; AF: atrial fibrillation; T2DM: type 2 diabetes mellitus